The US Food and Drug Administration has approved Lumizyme (alglucosidase alfa) to treat patients aged eight years and older with Pompe disease.

The genetic disorder is characterised by heart, skeletal and respiration weakness, often leading to death from respiratory failure.

Lumizyme works by replacing deficient acid alpha-glucosidase, an enzyme necessary for proper muscle GAA that is prevented by the gene mutation that characterises Pompe disease, thereby reducing the accumulated glycogen in heart and skeletal muscle cells.

Lumizyme has been approved with a risk evaluation and mitigation strategy and is available through a restricted distribution system to ensure that the drug is accessible only to the relevant patient group.

The safety and efficacy of Lumizyme was evaluated in a clinical study with 90 patients, ranging from ten years to 70 years.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.